The Relationship of single nucleotide polymorphisms in the Interleukin-7 receptor-alpha gene to CD4+ immune recovery in HIV infected patients who begin antiretroviral treatment with HAART

The Relationship of single nucleotide polymorphisms in the Interleukin-7 receptor-gene to CD4+ immune recovery in HIV infected patients who begin antiretroviral treatment with HAART

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12605000495628

Enrollment

Registered

2005-09-23

Start date

2005-08-15

Completion date

2008-09-27

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None. This is an observational study.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

First antiretroviral regimen composed of HAART as defined by at least three antiretrovirals. Controlled viremia for a period of at least 12 months following commencement of HAART. Controlled viremia is defined as HIV viral load of 500 copies/mL on bDNA testing (versions 2 and 3) and <400 copies/ml measured by RT-PCR assay by 6 months treatment. CD4 cell count <500 at commencement of HAART. Measurement of CD4+ cell count on at least 3 time points, in the 12 months post commencement of HAART.

Exclusion criteria

Exclude patients treated for HIV seroconversion illness. Exclude patients on immunomodulatory therapy such as IL-2, hydroxyurea or prednisolone or who have received an HIV therapeutic vaccine.

Outcome results